ClinicalTrials.gg
CompletedNCT00507416UPFRONTUpdated May 1, 2014Results posted

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

A Phase 3 interventional study of Bortezomib and Dexamethasone in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 235 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-01.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
502
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
17th of 373
502 · median 45
Started
2007
with 12 others
Phase 3
53 of 381
3 open now
Registered
58th of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 17th largest by enrollment of the 373 interventional ones that give a count, is one of 13 that started in 2007, is one of 53 in phase 3, and was the 58th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a randomized, open label, multicenter clinical trial to compare the efficacy and safety of Velcade (bortezomib) and dexamethasone versus Velcade, thalidomide, and dexamethasone versus Velcade, melphalan, and prednisone in patients with previously untreated multiple myeloma not considered candidates for high-dose chemotherapy and autologous stem cell transplantation.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 years of age or older
  • Not a candidate for high-dose chemotherapy and stem cell transplantation (HDT/SCT) due to age, presence of important comorbid condition(s) likely to have a negative impact on tolerability of HDT-SCT, or subject preference.
  • A Performance Status score of ≥50%
  • Symptomatic multiple myeloma or asymptomatic multiple myeloma with related organ or tissue damage.
  • Asymptomatic multiple myeloma-related organ or tissue damage can include presence of an asymptomatic lytic bone lesion or plasmacytoma, the presence of anemia ( \<10 g/dL), renal function impairment (serum creatinine > [ULN]) or hypercalcemia (serum calcium >ULN).
  • Must have requiring systemic therapy. Measurable disease is defined by at least 1 of the following criteria:

    • Quantifiable serum M-protein value (>1 g/dL of immunoglobulin (Ig)G or IgM M-protein, >0.5g/dL of IgA M-protein, >0.5 g/dL of IgD M-protein)
    • Urine light-chain excretion ≥200 mg/24 hours
  • Voluntary written must be given before performance of any study related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of smoldering multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS). Smoldering multiple myeloma is defined as asymptomatic multiple myeloma with absence of lytic bone lesions. MGUS is defined by presence of serum monoclonal protein \<3 g/dL; absence of lytic bone lesions, anemia, hypercalcemia, and renal insufficiency related to the monoclonal protein; and (if determined) proportion of plasma cells in the bone marrow of 10% or less.
  • Diagnosis of Waldenström's disease or other conditions in which immunoglobulin M (IgM) M-protein is present in the absence of a clonal plasma cell infiltration or lytic bone lesions.
  • Previously or currently treated with any systemic therapy for multiple myeloma. Prior treatment of hypercalcemia or spinal cord compression with or radiation therapy, respectively, does not disqualify the subject (the dose of corticosteroids should not exceed the equivalent of 160 mg of dexamethasone in 2-week period).
  • Radiation therapy within 2 weeks before randomization. Enrollment of patients who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 2 weeks have elapsed since the last date of therapy.
  • Major surgery within 30 days before randomization (Kyphoplasty is not considered major surgery)
  • History of allergy to any of the study medications, their analogues, or in the various formulations
  • ≥Grade 2 peripheral neuropathy on clinical examination within 21 days before enrollment.
  • Any of the following clinical laboratory values within 21 days prior to enrollment:

    • (ANC) \<1000 cells/mm\^3
    • \<100,000 × 10\^9/L, or \<70 × 10\^9/L if thrombocytopenia is considered by the investigator to be due to myeloma infiltration of bone marrow
    • [serum glutamic oxaloacetic transaminase] (AST [SGOT]) or alanine aminotransferase [serum glutamic-pyruvic transaminase] (ALT [SGPT]) >2× the (ULN)
    • Serum creatinine >2 mg/dL (>176.8 µmol/L); if the rise in creatinine is related to myeloma and there has been demonstrated a response to hydration, the subject may be enrolled.
  • Myocardial infarction within 6 months prior to enrollment or New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities in the opinion of the investigator. Prior to study entry, any abnormality on at screening must be determined and documented by the investigator as not medically relevant.
  • Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the patient at unacceptable risk if he/she were to participate in the study. This includes but is not limited to serious medical conditions or psychiatric illness likely to interfere with participation in this clinical study.
  • Prior except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer, or other cancer for which the patient has been disease-free for at least 3 years.
  • Female who is pregnant or breastfeeding. Female participants of must have a negative pregnancy test with a sensitivity of at least 50 mIU/mL during Screening.
  • Use of any drugs within 30 days before randomization.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
502 participants (actual)

Study arms

  • Experimental
    Bortezomib and Dexamethasone (VD)

    Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).

    Drug: Bortezomib · Drug: Dexamethasone

  • Experimental
    Bortezomib, Thalidomide, and Dexamethasone (VTD)

    Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .

    Drug: Bortezomib · Drug: Dexamethasone · Drug: Thalidomide

  • Experimental
    Bortezomib, Melphalan and Prednisone (VMP)

    Participants received bortezomib (Velcade) 1.3 mg/m\^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m\^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m\^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/\^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).

    Drug: Bortezomib · Drug: Melphalan · Drug: Prednisone

Interventions

  • Bortezomib bolus intravenous (IV) injection

    Also known as: Velcade

  • Dexamethasone for oral administration

  • Melphalan for oral administration

  • Prednisone for oral administration

  • Thalidomide for oral administration

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from randomization to disease progression or death, whichever occurs first. Participants who did not progress and were still alive at the cut-off date were censored at the date of last contact. Response was assessed by the Investigator using the International Myeloma Working Group (IMWG) uniform response criteria. Progressive disease requires 1 of the following: * Increase of ≥ 25% from nadir in: * Serum M-component (absolute increase ≥ 0.5 g/dl) * Urine M-component (absolute increase ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \> 100 mg/dl) * Bone marrow plasma cell percentage (absolute % ≥ 10%) * Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease

    Time frame: From randomization until disease progression. Median follow-up time was 43 months.

Secondary outcomes

  1. Percentage of Participants With an Overall Response

    Overall response defined as a best overall response of complete response (CR), very good partial response (VGPR) or partial response (PR), assessed by the Investigator using the IMWG uniform response criteria. CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours (h). PR requires 1 of the following: * ≥50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \<200 mg/24 h, or * If M-protein not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels, or * If FLC not measurable, a ≥ 50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%. If present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: Response assessed every other cycle for up to 13 cycles (49 weeks).

  2. Percentage of Participants With a Complete Response

    Participants with a best overall response of complete response, defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Response was assessed by the Investigator using the IMWG uniform response criteria.

    Time frame: Response assessed every other cycle, for up to 13 cycles (49 weeks).

  3. Percentage of Participants With a Complete Response or a Very Good Partial Response

    Complete response is defined by negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Very good partial response is defined by serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. Response was assessed by the Investigator using the IMWG uniform response criteria.

    Time frame: Response assessed every other cycle for up to 13 cycles (49 weeks).

  4. Duration of Response

    Duration of response is defined in participants with an overall response as the time between first documentation of response and disease progression. Responders without disease progression were censored at the last clinical assessment of response.

    Time frame: From first documented response until disease progression. Median follow-up time was 43 months.

  5. Overall Survival

    Overall survival is defined as the time between randomization and death. Participants still alive at the cutoff date or lost to follow-up were censored at the date of last contact.

    Time frame: From randomization until death. Median follow-up time was 43 months.

  6. Time to Alternative Therapy

    Time to alternative therapy is defined as the time between randomization and alternative therapy. Participants who did not receive alternative therapy were censored at the time of last contact.

    Time frame: From randomization until alternative therapy. Median follow-up time was 43 months.

  7. Change From Baseline in EORTC QLQ-C30 - Global Health Status

    The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement.

    Time frame: Baseline and Day 1 of Cycles 3, 5, 7, 9, 11 and 13

07

Results

Posted May 1, 2014

Participant flow

Participants took part in the study at 158 investigative sites in the United States from 26 June 2007 to 28 March 2013

Participant flow — Overall Study
MilestoneBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Started168167167
Treated (safety population)165158163
Completed 8 treatment cycles826069
Completed504253
Not completed118125114
Withdrew: Adverse event586765
Withdrew: Protocol violation120
Withdrew: Lack ofefficacy / physician decision778
Withdrew: Progressive disease201013
Withdrew: Patient declined further treatment181411
Withdrew: Other111613
Withdrew: Did not receive study treatment394

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from randomization to disease progression or death, whichever occurs first. Participants who did not progress and were still alive at the cut-off date were censored at the date of last contact. Response was assessed by the Investigator using the International Myeloma Working Group (IMWG) uniform response criteria. Progressive disease requires 1 of the following: * Increase of ≥ 25% from nadir in: * Serum M-component (absolute increase ≥ 0.5 g/dl) * Urine M-component (absolute increase ≥ 200 mg/24 hours) * In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase \> 100 mg/dl) * Bone marrow plasma cell percentage (absolute % ≥ 10%) * Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dl) attributed solely to plasma cell proliferative disease

Time frame:
From randomization until disease progression. Median follow-up time was 43 months.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Progression Free Survival (PFS)14.7 (12.0 to 18.6)15.4 (12.6 to 24.2)17.3 (14.8 to 20.3)
Statistical analysis
  • Bortezomib and Dexamethasone vs Bortezomib, Thalidomide, and Dexamethasone vs Bortezomib, Melphalan and Prednisone · Wald test · p = 0.458 (The global difference among arms was based on the Wald test.)
SecondaryPercentage of Participants With an Overall Response

Overall response defined as a best overall response of complete response (CR), very good partial response (VGPR) or partial response (PR), assessed by the Investigator using the IMWG uniform response criteria. CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours (h). PR requires 1 of the following: * ≥50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \<200 mg/24 h, or * If M-protein not measurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels, or * If FLC not measurable, a ≥ 50% reduction in plasma cells, provided baseline bone marrow plasma cell percentage was ≥30%. If present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
Response assessed every other cycle for up to 13 cycles (49 weeks).
Reported as:
Number · percentage of participants
Percentage of Participants With an Overall Response
percentage of participantsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Percentage of Participants With an Overall Response738070
SecondaryPercentage of Participants With a Complete Response

Participants with a best overall response of complete response, defined as negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Response was assessed by the Investigator using the IMWG uniform response criteria.

Time frame:
Response assessed every other cycle, for up to 13 cycles (49 weeks).
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response
percentage of participantsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Percentage of Participants With a Complete Response344
SecondaryPercentage of Participants With a Complete Response or a Very Good Partial Response

Complete response is defined by negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and \<5% plasma cells in bone marrow. Very good partial response is defined by serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours. Response was assessed by the Investigator using the IMWG uniform response criteria.

Time frame:
Response assessed every other cycle for up to 13 cycles (49 weeks).
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response or a Very Good Partial Response
percentage of participantsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Percentage of Participants With a Complete Response or a Very Good Partial Response375141
SecondaryDuration of Response

Duration of response is defined in participants with an overall response as the time between first documentation of response and disease progression. Responders without disease progression were censored at the last clinical assessment of response.

Time frame:
From first documented response until disease progression. Median follow-up time was 43 months.
Reported as:
Median · months
Duration of Response
monthsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Duration of Response18.3 (14.3 to 24.2)22.4 (12.7 to 29.1)19.8 (16.4 to 23.3)
SecondaryOverall Survival

Overall survival is defined as the time between randomization and death. Participants still alive at the cutoff date or lost to follow-up were censored at the date of last contact.

Time frame:
From randomization until death. Median follow-up time was 43 months.
Reported as:
Median · months
Overall Survival
monthsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Overall Survival49.8 (35.7 to NA)51.5 (38.5 to NA)53.1 (41.1 to NA)
SecondaryTime to Alternative Therapy

Time to alternative therapy is defined as the time between randomization and alternative therapy. Participants who did not receive alternative therapy were censored at the time of last contact.

Time frame:
From randomization until alternative therapy. Median follow-up time was 43 months.
Reported as:
Median · months
Time to Alternative Therapy
monthsBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Time to Alternative Therapy19.7 (16.0 to 27.8)24.5 (16.6 to 27.6)19.0 (15.2 to 23.1)
SecondaryChange From Baseline in EORTC QLQ-C30 - Global Health Status

The European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL Scale is scored between 0 and 100, where higher scores indicate better Global Health Status/QOL. Negative changes from baseline indicate deterioration in QOL or functioning and positive changes indicate improvement.

Time frame:
Baseline and Day 1 of Cycles 3, 5, 7, 9, 11 and 13
Reported as:
Mean · units on a scale
Change From Baseline in EORTC QLQ-C30 - Global Health Status
units on a scaleBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
Cycle 3, Day 1 (n=129, 115, 125)1.3 ± 25.40-4.4 ± 27.042.0 ± 30.82
Cycle 5, Day 1 (n=114, 98, 107)-4.9 ± 30.36-6.1 ± 27.47-0.4 ± 29.24
Cycle 7, Day 1 (n=89, 79, 84)-3.3 ± 32.58-8.6 ± 31.86-4.7 ± 28.61
Cycle 9, Day 1 (n=87, 66, 67)-4.2 ± 33.55-8.1 ± 28.16-1.0 ± 28.55
Cycle 11, Day 1 (n=71, 61, 65)-11.6 ± 33.67-7.9 ± 29.542.8 ± 31.72
Cycle 13, Day 1 (n=67, 52, 61)-10.2 ± 36.00-8.5 ± 32.871.0 ± 35.16

Adverse events

Collected over Adverse events were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 49 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib and Dexamethasone—88/165 (53.3%)57/165 (34.5%)
Bortezomib, Thalidomide, and Dexamethasone—92/158 (58.2%)68/158 (43%)
Bortezomib, Melphalan and Prednisone—83/163 (50.9%)68/163 (41.7%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
PneumoniaInfections and infestations18/16512/15810/163
DiarrhoeaGastrointestinal disorders12/1655/1588/163
DehydrationMetabolism and nutrition disorders8/1656/1589/163
Cardiac failure congestiveCardiac disorders7/1658/1581/163
Atrial fibrillationCardiac disorders7/1657/1581/163
PyrexiaGeneral disorders7/1652/1582/163
Deep vein thrombosisVascular disorders7/1654/1582/163
AnaemiaBlood and lymphatic system disorders4/1656/1582/163
VomitingGastrointestinal disorders3/1655/1586/163
HypotensionVascular disorders3/1653/1586/163
Most frequent other events
Showing 10 of 200
Most frequent other events
EventBortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and Prednisone
LeukopeniaBlood and lymphatic system disorders2/1651/15812/163
InsomniaPsychiatric disorders9/1656/1586/163
HyperuricaemiaMetabolism and nutrition disorders3/1658/1584/163
Platelet count decreasedInvestigations3/1651/1587/163
Weight decreasedInvestigations4/1652/1586/163
Neutrophil count decreasedInvestigations0/1650/1586/163
Rash pruriticSkin and subcutaneous tissue disorders0/1655/1583/163
CoughRespiratory, thoracic and mediastinal disorders3/1655/1583/163
Vision blurredEye disorders3/1655/1581/163
DysgeusiaNervous system disorders2/1654/1582/163

Baseline characteristics

Intention to treat population, defined as all participants randomized

Age, Continuous
Age, Continuous(years)Bortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and PrednisoneTotal
Mean72.6 ± 9.3571.3 ± 8.7371.3 ± 8.6771.7 ± 8.92
Age, Customized
Age, Customized(participants)Bortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and PrednisoneTotal
≥ 65 years140135139414
≥ 75 years846462210
≥ 80 years40272390
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and PrednisoneTotal
Female679777241
Male1017090261
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Bortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and PrednisoneTotal
White131124118373
Black23312983
Native Hawaiian or Other Pacific Islander0022
Asian2103
American Indian or Alaskan Native0123
Other10101535
Not Reported2013
Region of Enrollment
Region of Enrollment(participants)Bortezomib and DexamethasoneBortezomib, Thalidomide, and DexamethasoneBortezomib, Melphalan and PrednisoneTotal
United States168167167502
08

Study locations

235 sites
  • Birmingham Hematology Oncology Assciates, LLC
    Birmingham, Alabama 35205, United States
  • Desert Oasis Cancer Center
    Casa Grande, Arizona 85222, United States
  • Northern Arizona Hematology & Oncology Associates - AOA
    Sedona, Arizona 86336, United States
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • Heritage Physician Group Oncology
    Hot Springs, Arkansas 71913, United States
  • Hematology Oncology Services of Arkansas
    Little Rock, Arkansas 72205, United States
  • Pacific Cancer Medical Centre
    Anaheim, California 92801, United States
  • Tower Cancer Research Foundation
    Beverly Hills, California 90211-1850, United States
  • Compassionate Cancer Care Medical Group
    Corona, California 92882, United States
  • Compassionate Cancer Care Medical Group, Inc.
    Fountain Valley, California 92708, United States
  • Robert A. Moss, MD, FACP, Inc.
    Fountain Valley, California 92708, United States
  • Cancer Care Associates
    Fresno, California 93720, United States
  • Glendale Memorial Hospital & Health Center
    Glendale, California 91204, United States
  • California Cancer Care
    Greenbrae, California 94904, United States
  • Beaver Medical Group
    Highland, California 92346, United States
  • Edward A. Wagner, MD
    Laguna Beach, California 92882, United States
  • Clinical Trials and Research Associates, Inc.
    Montebello, California 90640, United States
  • Medical Oncology Care Associates
    Orange, California 92868, United States
  • Ventura County Hematology Oncology Specialists
    Oxnard, California 93030, United States
  • Southwest Cancer Care
    Poway, California 92064, United States
  • Desert Cancer Care, Incorporated
    Rancho Mirage, California 92270, United States
  • Compassionate Cancer Care Medical Group, Inc.
    Riverside, California 92501, United States
  • Sutter Cancer Center
    Sacramento, California 95816, United States
  • Cancer Research & Prevention Center
    Soquel, California 95073, United States
  • Stockton Hematology/Oncology
    Stockton, California 95204, United States
  • Trivalley Oncology Hematology
    Westlake Village, California 91361, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • Christiana Care Health Services
    Newark, Delaware 19718, United States
  • The Center for Hematology-Oncology
    Boca Raton, Florida 33486, United States
  • Pasco Hernando Oncology
    Brooksville, Florida 34613, United States
  • Northwest Oncology & Hematology Associates
    Coral Springs, Florida 33065, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Horizon Institute for Clinical Research
    Hollywood, Florida 33021, United States
  • Baptist Cancer Institute
    Jacksonville, Florida 32207, United States
  • University of Florida- Jacksonville
    Jacksonville, Florida 32209, United States
  • Cancer Care of North Florida
    Lake City, Florida 32024, United States
  • Lakeland Regional Cancer Center
    Lakeland, Florida 33805, United States
  • Cancer & Blood Disease Center
    Lecanto, Florida 34461, United States
  • Pasco Hernando Oncology
    New Port Richey, Florida 34652, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Innovative Medical Research of South Florida Inc.
    North Miami Beach, Florida 33179, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • MD Anderson Cancer Center Orlando
    Orlando, Florida 32806, United States
  • Hematology Oncology Associates of the Treasure Coast, PA
    Port St. Lucie, Florida 34952, United States
  • Gulfcoast Oncology Associates
    St. Petersburg, Florida 33705, United States
  • S. Florida Oncology/ Hematology
    West Palm Beach, Florida 33458, United States
  • Medical Oncology Associates of Augusta
    Augusta, Georgia 30901, United States
  • Central Georgia Cancer Care
    Macon, Georgia 31201, United States
  • Northwest Georgia Oncology Centers, P.C.
    Marietta, Georgia 30060, United States
  • Summit Cancer Care
    Savannah, Georgia 31405, United States
  • St. Lukes Mountain States Tumor Institute
    Boise, Idaho 83712, United States
  • Snake River Oncology of Eastern Idaho, PLLC.
    Idaho Falls, Idaho 83404, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Arlington Heights, Illinois 60005, United States
  • Hematology Oncology Associates of Illinois
    Chicago, Illinois 60611, United States
  • John H. Stroger, Jr. Hospital of Cook County
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Hematology Oncology Associates of Illinois
    Chicago, Illinois 60657, United States
  • Elmhurst Memorial Hospital
    Elmhurst, Illinois 60126, United States
  • Oncology Hematology Associates of North Illinois Ltd.
    Gurnee, Illinois 60031-3399, United States
  • Midwest Center for Hematology / Oncology
    Joliet, Illinois 60432, United States
  • Joliet Oncology-Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Hematology Oncology Consultants, Inc.
    Naperville, Illinois 60540, United States
  • Cancer Care and Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Mid-Illinois Hem & Onc
    Normal, Illinois 61761, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Deaconess Clinic Incorporated
    Evansville, Indiana 47713, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Investigative Clinical Research of Indiana, LLC
    Indianapolis, Indiana 46254, United States
  • Clarian Arnett Cancer Center
    Lafayette, Indiana 47904, United States
  • Medical Consultants, PC
    Muncie, Indiana 47303, United States
  • Cancer Care Center
    New Albany, Indiana 47150, United States
  • Memorial Hospital of South Bend
    South Bend, Indiana 46601, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • McFarland Clinic, P.C.
    Ames, Iowa 50010, United States
  • Heartland Hematology-Oncology Associates, Inc.
    Council Bluffs, Iowa 51503, United States
  • Siouxland Hematology/Oncology Assoc., LLP
    Sioux City, Iowa 51101, United States
  • Kansas City Cancer Centers - Southwest
    Overland Park, Kansas 66210, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214, United States
  • Commonwealth Cancer Center
    Danville, Kentucky 40422, United States
  • Kentucky Cancer Clinic
    Hazard, Kentucky 41701, United States
  • Western Kentucky Hematology and Oncology Group
    Paducah, Kentucky 42003, United States
  • Christus St. Francis Cabrini Cancer Center
    Alexandria, Louisiana 71301, United States
  • Hematology-Oncology Clinic
    Baton Rouge, Louisiana 70809, United States
  • Annapolis Oncology Center
    Annapolis, Maryland 21401, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • St. Agnes Health Care
    Baltimore, Maryland 21229, United States
  • Auerbach Hematology Oncology Associates
    Baltimore, Maryland 21237, United States
  • Maryland Hematology Oncology Association
    Baltimore, Maryland 21237, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Oncology-Hematology Associates, P.A.
    Clinton, Maryland 20735, United States
  • Maryland Oncology Hematology, PA
    Columbia, Maryland 21044, United States
  • Carroll County Cancer Center
    Westminster, Maryland 21157, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Fallon Clinic at Worcester Medical Center
    Worcester, Massachusetts 01608-1320, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Cancer & Hematology Centers of Western Michigan
    Grand Rapids, Michigan 49546, United States
  • Kalamazoo Hematology and Oncology
    Kalamazoo, Michigan 49048, United States
  • Hematology Oncology Associates of Ohio & Michigan, PC
    Lambertville, Michigan 48144, United States

Showing the first 100 of 235 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens. J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8. PubMed 26056177 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2007
First posted
Jul 26, 2007
Start
Jun 2007
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
May 1, 2014
Last update
May 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00507416
Responsible party
Sponsor
First posted
Jul 26, 2007
Start date
Jun 2007
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
May 1, 2014
Last update
May 1, 2014

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Melphalan · Prednisone · Thalidomide

Start the discussion